Over 400 delegates working in biosimilars and biobetters, proteins, antibodies and peptides, representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions.

Over 20 presentations and case studies focusing on the key areas of the biosimilars industry.

Two-day interactive conference addressing the following topics:

• Market Access Strategies, Opportunities And Commercial Challenges
• Developing Biosimilars And Biobetters

Co-located with the 9th Annual Proteins & Antibodies Congress and 3rd Annual Peptides Congress

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present the 4th Annual Biosimilars & Biobetters Congress, taking place on the 18th & 19th April 2016 at the Novotel London West, UK. Together with the Proteins & Antibodies Congress and the Peptides Congress, the 3 events provide a unique opportunity for over 350 global leaders in the biologics industry to exchange knowledge and experience, share their ideas on innovative practices, and benefit from engaging networking opportunities with peers in the biosimilars and biologics field.

The rate at which biosimilars are being developed and approved is gaining momentum, and the industry is likely to reach a projected value of up to $20 billion by 2020. As ever more biosimilars reach the clinical and commercial stages, we will bring together key scientific and business minds to address the major challenges and most exciting opportunities that lie ahead for the industry.

Day One will explore business and commercial aspects of the biosimilar landscape, with topics including key market access and regulatory issues. Our esteemed panel of expert speakers will cover updates on biosimilar and biobetter competition, legal affairs, and market strategies, and how these areas are affecting those working in the industry right now. Global access difficulties and the future possibilities for the biosimilars products will be discussed by those who are the forefront of the field.

Day Two will look at the development of both biosimilar and biobetter products at preclinical and clinical stages. Representatives from leading international biosimilar industry organisations will provide exciting case studies detailing the planning and execution of effective biosimilar clinical trials, as well as looking at the optimisation of analytical testing in the preclinical phase to better advance the approval of products.

The 4th Annual Biosimilars & Biobetters Congress forms part of Oxford Global’s highly successful Biologics Series.